Any patient can develop OUD and patients with OUD are at higher risk for overdose.1 Personal history, length of therapy, and dosage play a role in the development of OUD.2 A physician’s effectiveness in treating the underlying cause of a patient’s pain can be a crucial aspect of the defense in an opioid overdose case.
In this case, experts surmised that the patient in the following case had developed OUD at some point during the course of treatment with his family practice physician (FP). The FP maintained that his prescribing was appropriate and the patient would not have died if he had taken his medications appropriately. However, the experts believed the FP’s duty to appropriately treat the patient extended beyond simply writing out prescriptions.
The FP prescribed an excessive amount of pain medications, failed to refer the patient for addiction and psychiatric treatment, and failed to discover that the patient had been obtaining pain medications from another physician.
In 2012 a man with bronchitis, migraines, depression, and a history of past treatment for alcohol abuse disorder started treatment with an FP. His medications included duloxetine for depression, nortriptyline for stress-related migraines, alprazolam for anxiety, and zolpidem as a sleep aid, all of which the FP planned to continue. In 2016, the patient had knee surgery. His surgeon prescribed hydrocodone-acetaminophen as needed for post-surgical pain. At the patient’s request, the FP refilled the prescription every month thereafter. The FP was not aware that the patient was also seeing a pain management specialist, who was prescribing hydrocodone-acetaminophen. If the patient took the prescriptions as directed by the FP and pain management specialist, his morphine milligram equivalents per day (MME/day) would be 80-120.
In 2018, the FP prescribed hydrocodone-chlorpheniramine syrup for coughing related to bronchitis. The next day, the patient died of an overdose. The cough syrup bottle was found at his bedside. Based on what was left in the bottle, it appeared he had taken six times the recommended dosage. The cause of death was determined to be toxicity due to hydrocodone, nortriptyline, alprazolam, zolpidem, and chlorpheniramine.
The patient’s family filed a wrongful death lawsuit claiming the FP prescribed an excessive amount of pain medications, failed to refer the patient for addiction and psychiatric treatment (which he was allegedly unqualified to treat), and failed to discover that the patient had been obtaining pain, sleep, and anxiety medications from another physician.
Experts believed various aspects of the FP’s management of this patient did not meet the standard of care. For example, the FP failed to access the state prescription drug monitoring program (PDMP) website. Had he done so, he would have discovered that the patient was obtaining opioids from another source. Additionally, the FP continued to prescribe hydrocodone-acetaminophen without ever assessing the patient for substance abuse disorder or pain management. Furthermore, although the FP prescribed duloxetine, alprazolam, and zolpidem, there was no indication the patient’s behavioral health was assessed, or that the effectiveness of the psychiatric medications was evaluated.
The fact that the FP prescribed hydrocodone-chlorpheniramine syrup the day before the patient’s overdose made the defense of this lawsuit particularly challenging because it appeared that the cough syrup, when combined the other prescription medications, was the primary cause of the patient’s overdose.
A major concern of the consultants reviewing the following case was the physician’s apparent failure to address the patient’s poorly controlled diabetes as an element of managing the patient’s pain associated with diabetic peripheral neuropathy.
The internist negligently prescribed excessive narcotic medications without proper checks and balances following the patient’s treatment for opioid addiction.
A patient’s internist had been prescribing oxycodone as needed for his patient’s diabetic peripheral neuropathy for many years. In March 2017 the patient checked herself into an opioid addiction rehabilitation facility. Following treatment the patient was opioid free until June 2018 when she had surgery. Her surgeon prescribed hydromorphone, fentanyl patch, and codeine/acetaminophen for post-surgical pain relief (MME/day = 230). Thereafter, the internist refilled the prescriptions until the patient accidentally overdosed in September 2018. Her cause of death was determined to be mixed prescription intoxication.
The patient’s husband filed a wrongful death lawsuit alleging the internist prescribed excessive narcotic medications without proper checks and balances to ensure that abuse was not occurring and that he negligently prescribed narcotics following OUD treatment and caused the plaintiff’s wife to become addicted again, which increased her risk of accidental overdose.
Experts were critical of the internist for what they perceived to be a failure to properly treat the underlying causes of the patient’s pain, manage the patient’s pain, and refer the patient to a pain management specialist when it became apparent that the patient’s needs exceeded his level of expertise. There was no evidence in the patient’s record that the internist educated her about the relationship between poorly controlled diabetes and peripheral neuropathy or that he worked with her to improve her compliance.
Furthermore, experts believed it was below the standard of care to prescribe pain medications with no treatment plan, substance use disorder (SUD) screening, therapeutic agreement, long-term goals, or prescription drug monitoring program (PDMP) review. Significantly, the patient had managed without opioid pain medications for over a year following opioid addiction treatment but, instead of providing an alternative to opioids for acute pain following surgery, the internist refilled her opioid prescriptions. Experts believed this was inconsistent with the standard of care.
Reducing the risk of accidental overdose in a chronic pain patient on opioid therapy requires a multimodal approach including: assessment of the medical and the probable biopsychosocial factors causing or contributing to the patient’s pain; substance abuse and suicide risk; development of a treatment plan; utilizing alternatives to addictive medications; establishment of treatment goals; monitoring for treatment efficacy and opioid use disorder; and referral when appropriate. The patient must be engaged in a thorough informed consent process that covers the risks associated with opioid use, the expected benefits, uncertainties of the anticipated treatment plan, and the alternatives.
Ensuring that patients understand their role in the success of a pain management treatment plan is crucial. Educating family members and caregivers about the pain management process can also improve results.3 Documenting these efforts provides evidence of opioid therapy for pain management that is consistent with the standard of care in the unfortunate event of a patient overdose. Consider the following strategies:1,4,5,6,7,8
It’s important to note that proposing risk reduction strategies for pain management comes with the acknowledgement that some primary care practices may face limited referral options, insurance coverage for various pain management modalities, and clinician time to manage cases. It is important to realize, however, that lack of resources, insurance, options, etc. are not valid defenses to medical negligence. Primary care physicians cannot abdicate responsibility to address a patient’s complaints of pain – keeping in mind that addressing pain does not mean curing pain. Expectation management is important for all pain management patients, but crucial for legacy patients (patients who have been on long-term opioid therapy) in practices with limited resources. If a particular patient’s pain management is outside a physician’s scope, or resources cannot be accessed, the physician has to communicate that clearly and compassionately. A physician can state the needed care is “past my area of expertise and I need help managing your condition in the safest way possible.”
Appropriate documentation of efforts to accomplish pain management in a manner consistent with the standard of care is a crucial aspect of liability risk management in difficult circumstances. At a minimum, medical record documentation should include efforts to coordinate care and refer to specialists, the results of those efforts, and patient response to those efforts, as well as conversations with patients about waiting periods for specialty care referral and what can and cannot be done in the meantime.
The following is a sample of the many guidelines and tools available online that address opioid prescribing for chronic pain management.
U.S. Department of Health and Human Services 2019 Pain Management Best Practices Inter-Agency Task Force Report.
American Society of Interventional Pain Physicians. 2017 Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
United States Department of Veterans Affairs and the Department of Defense “Use of Opioids in the Management of Chronic Pain (2022)”
Safe Opioid Prescribing. U.S. Department of Health and Human Services. 2019.
Checklist for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention. 2020.
Managing Chronic Pain in Adults with or in Recovery from Substance Use Disorders: “Appendix B. Assessment Tools and Resources.” United States Substance Abuse and Mental Health Services Administration. 2012.
SCOPE of Pain. Boston University School of Medicine. 2019.
Pathways to Safer Opioid Use. U.S. Department of Health and Human Services. 2017.
More Information About Opioid Prescribing for Chronic Pain
|
References
1. National Quality Forum. Opioids and Opioid Use Disorder: An Environmental Scan of Quality Measures Final Report. September 12, 2019.
2. Stephanie Slat, Jennifer Thomas, et al. “Coronavirus Disease 2019 and Opioid Use — A Pandemic Within an Epidemic.” JAMA Health Forum. 2020;1(5):e200628. DOI: 10.1001/jamahealthforum.2020.0628.
3. U.S. Department of Health and Human Services. Pain Management Best Practices Inter-Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations. 2019.
4. Deborah Dowell, et. al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. Morbidity and Mortality Weekly Report (MMWR) Recommendations and Reports 2022;71(No. RR-3):1–95. November 4, 2022. DOI: 10.15585/mmwr.rr7103a1
5. National Institute on Drug Abuse (NIDA). “Improving Opioid Prescribing.” Policy Brief. March 30, 2017.
6. Fa-ngam Charoenpol, Nuj Tontisirin, et al. “Pain Experiences and Intrapersonal Change Among Patients with Chronic Non-Cancer Pain After Using a Pain Diary: A Mixed-Methods Study.” Journal of Pain Research. 2019;12:477-487. DOI: 10.2147/JPR.S186105.
7. Substance Abuse and Mental Health Services Administration. “TIP 54: Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders.” U.S. Department of Health and Human Services. Treatment Improvement Protocol (TIP) Series. Publication ID: SMA13-4671. 2012.
8. Federation of State Medical Boards. Guidelines for the Chronic Use of Opioid Analgesics. 2017.